Trius gets ex-Korean rights to Dong-A's oxazolidinones
Korean drug company Dong-A Pharmaceutical has licensed Trius Therapeutics (antibacterials) exclusive worldwide rights, excluding Korea, to develop, manufacture, and market a group of antibacterial compounds called oxazolidinones.
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.